Indoleamine-Pyrrole 2,3,-Dioxygenase
"Indoleamine-Pyrrole 2,3,-Dioxygenase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A dioxygenase with specificity for the oxidation of the indoleamine ring of TRYPTOPHAN. It is an extrahepatic enzyme that plays a role in metabolism as the first and rate limiting enzyme in the kynurenine pathway of TRYPTOPHAN catabolism.
| Descriptor ID |
D050503
|
| MeSH Number(s) |
D08.811.682.690.416.333
|
| Concept/Terms |
Indoleamine-Pyrrole 2,3,-Dioxygenase- Indoleamine-Pyrrole 2,3,-Dioxygenase
- Indolamine-2,3-Dioxygenase
- Indolamine 2,3 Dioxygenase
- Indoleamine-Oxygen 2,3-Oxidoreductase (Decyclizing)
- IDO Dioxygenase
- Dioxygenase, IDO
- Indoleamine 2,3-Dioxygenase
- Indoleamine 2,3 Dioxygenase
|
Below are MeSH descriptors whose meaning is more general than "Indoleamine-Pyrrole 2,3,-Dioxygenase".
Below are MeSH descriptors whose meaning is more specific than "Indoleamine-Pyrrole 2,3,-Dioxygenase".
This graph shows the total number of publications written about "Indoleamine-Pyrrole 2,3,-Dioxygenase" by people in this website by year, and whether "Indoleamine-Pyrrole 2,3,-Dioxygenase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 1 | 0 | 1 |
| 2012 | 1 | 1 | 2 |
| 2013 | 0 | 1 | 1 |
| 2014 | 2 | 1 | 3 |
| 2015 | 1 | 0 | 1 |
| 2016 | 0 | 2 | 2 |
| 2017 | 4 | 0 | 4 |
| 2018 | 3 | 1 | 4 |
| 2019 | 1 | 0 | 1 |
| 2020 | 3 | 1 | 4 |
| 2021 | 2 | 2 | 4 |
| 2022 | 2 | 2 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Indoleamine-Pyrrole 2,3,-Dioxygenase" by people in Profiles.
-
Identification and Characterization of a Novel Indoleamine 2,3-Dioxygenase 1 Protein Degrader for Glioblastoma. J Med Chem. 2022 12 08; 65(23):15642-15662.
-
Reshaping the tumor microenvironment with oncolytic viruses, positive regulation of the immune synapse, and blockade of the immunosuppressive oncometabolic circuitry. J Immunother Cancer. 2022 07; 10(7).
-
Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses. Sci Transl Med. 2022 03 16; 14(636):eabg8402.
-
The immunoregulatory landscape of human tuberculosis granulomas. Nat Immunol. 2022 02; 23(2):318-329.
-
Myeloid-Derived Suppressor Cells Mediate T Cell Dysfunction in Nonhuman Primate TB Granulomas. mBio. 2021 12 21; 12(6):e0318921.
-
Tumor Cell IDO Enhances Immune Suppression and Decreases Survival Independent of Tryptophan Metabolism in Glioblastoma. Clin Cancer Res. 2021 12 01; 27(23):6514-6528.
-
IDO1 Expression in Ovarian Cancer Induces PD-1 in T Cells via Aryl Hydrocarbon Receptor Activation. Front Immunol. 2021; 12:678999.
-
Tryptophan metabolism in brain tumors - IDO and beyond. Curr Opin Immunol. 2021 06; 70:57-66.
-
Indoleamine 2,3-Dioxygenase-1 Expression in Adrenocortical Carcinoma. J Surg Res. 2020 12; 256:90-95.
-
Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma. Clin Cancer Res. 2020 10 01; 26(19):5232-5245.